Skip to content
Screener

Pacira BioSciences, Inc. PCRX Business Segments — Total net product sales

Similar metrics at other companies

VGN
VGNTReportable Segment — Total Net Sales
$2.21B+9.3%
Primo Brands logo
PRMBReportable Segment — Total Net Sales
$1.8B+3.8%
Scotts Miracle-Gro logo
SMGReportable segment total — Net Sales
$789.88M-4.5%
Crown Holdings logo
CCKTotal reportable segments — Net Sales
$2.92B+12.5%
Madrigal Pharmaceuticals, Inc. logo
MDGLReportable Segment — Product revenue, net
$364.25M+71.2%
Insmed logo
INSMReportable Segment — Product revenues, net
$425.49M+296%

Other financials

Income statement

See full
Revenue$177.4M+5.0%
Gross profit$141.0M+4.7%
Operating income$6.9M+247%
Net income$2.9M-39.4%
EPS (diluted)$0.07-30.0%

Balance sheet

See full
Cash & equivalents$144.3M-49.1%
Total debt$411.2M+15.3%
Total equity$653.9M-18.1%
Total assets$1.2B-23.8%

Cash flow

See full
Operating cash flow$25.7M-27.6%
CapEx$2.7M-68.1%
Free cash flow$23.0M-14.7%

Valuation

See full
Market cap$1.02B+1.3%
Enterprise value$1.29B+21.7%
P/E198.5×
P/S1.4×0.0×

Profitability

See full
Gross margin79.3%+1.7pp
Operating margin3.3%
Net margin0.7%
FCF margin18.1%-4.6pp

Returns & leverage

See full
Return on equity0.7%
Debt / equity0.6×+0.2×
Current ratio4.7×+2.3×

Where this comes from

Reported directly by Pacira BioSciences, Inc. in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The source filing: Pacira BioSciences, Inc.’s 10-Q, filed April 30, 2026.

Filed
Apr 30, 2026, 4:07 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001628280-26-028871
Line itemThree Months Ended March 31, 20262025
Revenues$177,376$168,923
Less:
Adjusted cost of goods sold (1)34,77032,590
Adjusted research and development (1)25,36223,101
Adjusted selling and marketing (1)58,16655,571
Adjusted general and administrative (1)25,71220,609
Stock-based compensation (1)13,53914,553
Amortization of acquired intangible assets14,32214,322

Item 1. FINANCIAL STATEMENTS (Unaudited)

FAQ

What is Pacira BioSciences, Inc.'s business segments — total net product sales?
Pacira BioSciences, Inc. (PCRX) reported business segments — total net product sales of $177.38M in Q1 2026.
How has Pacira BioSciences, Inc.'s business segments — total net product sales changed year-over-year?
Pacira BioSciences, Inc.'s business segments — total net product sales increased by 5.0% year-over-year, from $168.92M to $177.38M.
What is the long-term trend for Pacira BioSciences, Inc.'s business segments — total net product sales?
Over 3 years (2022 to 2025), Pacira BioSciences, Inc.'s business segments — total net product sales has grown at a 2.9% compound annual growth rate (CAGR), from $666.82M to $726.41M.
What does business segments — total net product sales mean?
Represents the total revenue generated from the sale of products within a specific reportable business segment after accounting for returns, allowances, and discounts. This metric serves as the primary indicator of market demand and commercial performance for the segment's product portfolio.

Ask your AI about Pacira BioSciences, Inc.'s business segments — total net product sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude